\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

			ι	or Section 30(n) of th	lie inves	sinen	Company Ac	1 01 1940)			
1. Name and Address of Reporting Person* Canaan IX L.P.				2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [CTMX]						lationship of Report k all applicable) Director	0 ()	o Issuer 6 Owner
(Last) 285 RIVERSIE	(First) DE AVENUE,	(Middle) SUITE 250	בי (ב	3. Date of Earliest Transaction (Month/Day/Year) 11/23/2016						Officer (give title below)	e Oth bel	er (specify ow)
(Street) WESTPORT (City)	CT (State)	0688((Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)) 6. Ind Line) X	ividual or Joint/Grou Form filed by O Form filed by M Person	ne Reporting P	erson
		Table I -	Non-Derivativ	ve Securities A	Acquii	red, I	Disposed	of, or	Beneficially	Owned		
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock			11/23/2016		s		10,890	D	\$ 11.8385 ⁽¹⁾	3,694,036	I	See Footnote ⁽²⁾
Common Stock			11/25/2016		s		6,729	D	\$11.7909 ⁽³⁾	3,687,307	I	See Footnote ⁽²⁾

 Common Stock
 11/28/2016
 s
 s
 20,840
 D
 \$11.3312(4)
 3,666,467
 I
 See Footnote(2)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
	nd Address of <u>n IX L.P.</u>	Reporting Person [*]													
(Last) 285 RIV		(First) /ENUE, SUITE	(Middle) 250												
(Street) WESTPO	ORT	СТ	06880		_										
(City)		(State)	(Zip)		_										
	nd Address of <u>Partners</u>	Reporting Person [*]													
(Last)		(First)	(Middle)												

285 RIVERSIDE AVENUE, SUITE 250

(Street) WESTPORT	СТ	06880
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.3950 - \$12.05, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4.

2. The shares are held directly by Canaan IX L.P. (the "Canaan Fund"). Canaan Partners IX LLC ("Canaan IX" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund, and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors. Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.67 - \$12.07, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.11 - \$11.69, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

Remarks:

Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24 to the Form 4 filed by the Reporting Persons on October 12, 2016)

<u>Canaan IX L.P., By: Canaan</u>	
<u>Partners IX LLC, its general</u>	11/28/2016
<u>partner, By: /s/ Janine</u>	11/20/2010
MacDonald, Attorney-in-Fact	
Canaan Partners IX LLC, By:	
<u>/s/ Janine MacDonald,</u>	<u>11/28/2016</u>
Attorney-in-Fact	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.